Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
64
MAZE Quote, Financials, Valuation and Earnings
Last price:
$42.58
Seasonality move
:
--
Day range:
$40.88 - $43.29
52-week range:
$6.71 - $43.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
501.13x
P/B ratio:
5.40x
Volume:
516.9K
Avg. volume:
397.2K
1-year change:
--
Market cap:
$2B
Revenue:
$167.5M
EPS (TTM):
-$2.25
Analysts' Opinion
-
Consensus RatingMaze Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $43.25, Maze Therapeutics, Inc. has an estimated upside of 1.53% from its current price of $42.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $34.00 representing 20.19% downside risk from its current price of $42.60.
Fair Value
-
According to the consensus of 8 analysts, Maze Therapeutics, Inc. has 1.53% upside to fair value with a price target of $43.25 per share.
MAZE vs. S&P 500
-
Over the past 5 trading days, Maze Therapeutics, Inc. has overperformed the S&P 500 by 11.97% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Maze Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Maze Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Maze Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Maze Therapeutics, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Maze Therapeutics, Inc. reported earnings per share of -$0.63.
Enterprise value:
1.7B
EV / Invested capital:
4.19x
Price / LTM sales:
501.13x
EV / EBIT:
6.12x
EV / Revenue:
405.84x
PEG ratio (5yr expected):
-1.31x
EV / Free cash flow:
-15.65x
Price / Operating cash flow:
8.00x
Enterprise value / EBITDA:
5.77x
Gross Profit (TTM):
-$2.6M
Return On Assets:
-28.99%
Net Income Margin (TTM):
-2353.04%
Return On Equity:
-35.16%
Return On Invested Capital:
-30.65%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $2.5M | -- | $2.5M | -- | |
| Gross Profit | -$1M | -$1.2M | -$2.6M | $1.7M | -$571K | |
| Operating Income | -- | -$100.5M | -$134.6M | -$24.2M | -$33M | |
| EBITDA | -- | -$96.8M | -$132M | -$23.4M | -$32.4M | |
| Diluted EPS | -$0.57 | -$1.97 | -$2.25 | -$0.06 | -$0.63 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $154M | $391.3M | |
| Total Assets | -- | -- | -- | $192.5M | $422.1M | |
| Current Liabilities | -- | -- | -- | $17.6M | $22.1M | |
| Total Liabilities | -- | -- | -- | $93.1M | $42.6M | |
| Total Equity | -- | -- | -- | $99.4M | $379.4M | |
| Total Debt | -- | -- | -- | $74.5M | $19.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -$106.7M | -- | -$24.6M | |
| Cash From Investing | -- | -- | -$68.2M | -- | -$66.9M | |
| Cash From Financing | -- | -- | $342M | -- | $143.8M | |
| Free Cash Flow | -- | -- | -$108M | -- | -$24.7M | |
MAZE
Sector
Market Cap
$2B
--
Price % of 52-Week High
98.41%
--
Dividend Yield
0%
--
Shareholder Yield
-27.86%
--
1-Year Price Total Return
--
--
Beta (5-Year)
--
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$38.51
200-day SMA
Buy
Level
$17.58
Bollinger Bands (100)
Buy
Level
15.72 - 32.44
Chaikin Money Flow
Buy
Level
4.1M
20-day SMA
Buy
Level
$35.01
Relative Strength Index (RSI14)
Buy
Level
80.67
ADX Line
Buy
Level
32.25
Williams %R
Sell
Level
-5.8376
50-day SMA
Buy
Level
$31.44
MACD (12, 26)
Buy
Level
2.75
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
7.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (2.3699)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-7.7715)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.
Stock Forecast FAQ
In the current month, MAZE has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MAZE average analyst price target in the past 3 months is $43.25.
-
Where Will Maze Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Maze Therapeutics, Inc. share price will rise to $43.25 per share over the next 12 months.
-
What Do Analysts Say About Maze Therapeutics, Inc.?
Analysts are divided on their view about Maze Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Maze Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $34.00.
-
What Is Maze Therapeutics, Inc.'s Price Target?
The price target for Maze Therapeutics, Inc. over the next 1-year time period is forecast to be $43.25 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MAZE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Maze Therapeutics, Inc. is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MAZE?
You can purchase shares of Maze Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Maze Therapeutics, Inc. shares.
-
What Is The Maze Therapeutics, Inc. Share Price Today?
Maze Therapeutics, Inc. was last trading at $42.58 per share. This represents the most recent stock quote for Maze Therapeutics, Inc.. Yesterday, Maze Therapeutics, Inc. closed at $42.60 per share.
-
How To Buy Maze Therapeutics, Inc. Stock Online?
In order to purchase Maze Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MAZE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MAZE
Sector
P/E ratio
--
--
PEG ratio
-1.31x
--
P/B ratio
5.40x
--
Price / LTM sales
501.13x
--
Growth Metrics
MAZE
Sector
Revenue growth
-100%
--
Earnings growth
-1029.6%
--
Revenue (5-year growth)
--
--
Earnings forecast
-$0.69
--
Profitability
MAZE
Sector
Profitability FY 2024
$164.2M
--
Return on invested capital
-30.65%
--
Return on assets
-28.99%
--
Return on equity
-35.16%
--
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
MAZE
Sector
Total cash
$383.9M
--
Short term investments
--
--
Total assets
$240.5M
--
Long term debt
$19.4M
--
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 65.26% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 0.12% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is down 0.53% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
